Daxocox® is a
breakthrough pain
breakthrough

Daxocox® helps stop breakthrough
OA pain haunting dogs

Owner compliance

OWNER COMPLIANCE

Simple weekly dosing with a flavoured tablet

7x less risk of a missed dose, compared to daily dosing

Consistent plasma levels

CONSISTENT PLASMA LEVELS

Consistent Pain Control for 7 days

Reaches minimum effective concentration within 24 hours after the 1st dose and stays at the required therapeutic level for 7 days until the next dose is due5

Flare Ups

FLARE UPS

Reliable analgesia

A combination of compliance friendly administration and proven 7-day efficacy provides reassurance that the clinical consequences of unavoidable OA flare-ups are minimised

Disease Progression

DISEASE PROGRESSION

Licensed for all stages of OA

Can be given continuously, with no mandatory treatment breaks1, making Daxocox® a suitable NSAID cornerstone of a responsive multi-modal management approach

Daxocox® is effective

Once weekly dosing with Daxocox® achieves significant improvement of clinical signs associated with OA pain2,3

  • Owners report that 90% of dogs with OA improve after treatment with Daxocox® and 84% of dogs improved their quality of life from “poor or fair” to “good, very good or excellent”2
  • According to veterinary assessment 74% of the dogs do not show clinical signs of osteoarthrit is2

Clinical study design:

Multicentre, randomised, single blinded clinical field trials (x2) to assess the efficacy of Daxocox®

The study inclusion criteria included:

  • > 12 months
  • > 5kg body weight
  • Clinical signs of osteoarthritis for > 3 weeks
  • Confirmed radio graphic evidence of osteoarthritis
  • Minimum clinical sum scores (CSS)
  • Basal haematology and biochemistry within normal limits
  • Received no OA treatment or nutraceutical for an appropriate period of time prior to the study

Both veterinary and owner assessment of improvement was included:

  • The following clinical signs were assessed by vets separately, to generate a clinical sum score (CSS) at each examination:
    • Posture, stance and weight bearing
    • Lameness at walk
    • Lameness at trot
    • Pain on palpation and manipulation
  • Owners completed a subjective assessment, via a questionnaire with a series of set ‘ranking questions’, to generate comparable Canine Brief Pain inventory Scores and QoL analysis
    • Investigated perceived pain levels over varying time periods and during different daily activities

Daxocox® is well tolerated

Daxocox® has a broad margin of safety:

  • Clinical field trials noted that, as with all NSAIDs, adverse effects are mostly related to the gastrointestinal system and most cases recovered without treatment1
  • The target animal safety study demonstrates that administering up to 5x the recommended therapeutic dose did not show any relevant treatment related adverse effects4
  • Suitable for long-term use, with no evidence of drug over-accumulation and no need for therapeutic breaks1

Elevated blood urea and serum cholesterol levels were observed in some cases, at both the recommended dose and overdose.

In case of adverse reactions, the use of the veterinary medicinal product should be stopped and general supportive therapy, as for clinical overdose with NSAIDs, should be applied until complete resolution of the signs.

Daxocox product